Objective: To investigate whether a significantly aberrant expression of circulating placental mRNA genes related with cardiogenesis can be detected at the second trimester of pregnancy. Methods: The study was performed in two stages. First stage (development model group): match of 14 placental tissues at delivery of fetuses with congenital heart disease versus 20 controls. Second stage (validation model group): mRNA amplification of abnormal expressed genes in maternal blood samples from 26 women bearing a fetus with a congenital heart disease matched with 28 controls. Results: We identified four functional categories of genes possibly involved in abnormal heart development: cardiac morphogenesis: tenascin, thioredoxin, salvador homolog 1 protein; extracellular matrix (ECM) and valvular tissue biosynthesis; placental-associated plasma protein, collagen, type I, alpha 2, fibulin-1, heparanase, procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha polypeptide II, Jumonji, AT rich interactive domain 1B RBP2-like; normal contractile activity: actinin, alpha 4, fascin homolog 1, actin-bundling protein; and congestive heart failure. Conclusion: Altered placental genetic expression was found at term delivery in affected fetuses. The aberration was also confirmed in maternal blood at the second trimester of women bearing a fetus with congenital heart disease. Sensitivity for the most aberrant genes ranged between 42% and 95% at a false positive rate (FPR) of 10%. Copyright © 2010 John Wiley & Sons, Ltd.

Arcelli, D., Farina, A., Cappuzzello, C., Bresin, A., De Sanctis, P., Perolo, A., et al. (2010). Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: Implications for early molecular screening. PRENATAL DIAGNOSIS, 30(3), 229-234 [10.1002/pd.2443].

Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: Implications for early molecular screening

CAPPUZZELLO, CLAUDIA;
2010

Abstract

Objective: To investigate whether a significantly aberrant expression of circulating placental mRNA genes related with cardiogenesis can be detected at the second trimester of pregnancy. Methods: The study was performed in two stages. First stage (development model group): match of 14 placental tissues at delivery of fetuses with congenital heart disease versus 20 controls. Second stage (validation model group): mRNA amplification of abnormal expressed genes in maternal blood samples from 26 women bearing a fetus with a congenital heart disease matched with 28 controls. Results: We identified four functional categories of genes possibly involved in abnormal heart development: cardiac morphogenesis: tenascin, thioredoxin, salvador homolog 1 protein; extracellular matrix (ECM) and valvular tissue biosynthesis; placental-associated plasma protein, collagen, type I, alpha 2, fibulin-1, heparanase, procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha polypeptide II, Jumonji, AT rich interactive domain 1B RBP2-like; normal contractile activity: actinin, alpha 4, fascin homolog 1, actin-bundling protein; and congestive heart failure. Conclusion: Altered placental genetic expression was found at term delivery in affected fetuses. The aberration was also confirmed in maternal blood at the second trimester of women bearing a fetus with congenital heart disease. Sensitivity for the most aberrant genes ranged between 42% and 95% at a false positive rate (FPR) of 10%. Copyright © 2010 John Wiley & Sons, Ltd.
Articolo in rivista - Articolo scientifico
Congenital heart diseases; Microarrays; Molecular screening; Placental mRNA; Biological Markers; Female; Fetal Diseases; Gene Expression Profiling; Genetic Testing; Heart Defects, Congenital; Humans; Maternal-Fetal Exchange; Molecular Diagnostic Techniques; Oligonucleotide Array Sequence Analysis; Placenta; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, Second; RNA, Messenger; Retrospective Studies; Genetics (clinical); Obstetrics and Gynecology;
English
2010
30
3
229
234
none
Arcelli, D., Farina, A., Cappuzzello, C., Bresin, A., De Sanctis, P., Perolo, A., et al. (2010). Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: Implications for early molecular screening. PRENATAL DIAGNOSIS, 30(3), 229-234 [10.1002/pd.2443].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/70271
Citazioni
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
Social impact